PEG3 Antibody (OTI1E10) [FITC]
Novus Biologicals, part of Bio-Techne | Catalog # NBP2-73333F
Conjugate
Catalog #
Forumulation
Catalog #
Key Product Details
Species Reactivity
Human
Applications
Immunohistochemistry, Immunohistochemistry-Paraffin, Western Blot
Label
FITC (Excitation = 495 nm, Emission = 519 nm)
Antibody Source
Monoclonal Mouse IgG1 Clone # OTI1E10
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Product Specifications
Immunogen
Recombinant protein fragment corresponding to amino acids 1-364 of human PEG3 (NP_006201) produced in E.coli.
Clonality
Monoclonal
Host
Mouse
Isotype
IgG1
Applications for PEG3 Antibody (OTI1E10) [FITC]
Application
Recommended Usage
Immunohistochemistry
Optimal dilutions of this antibody should be experimentally determined.
Immunohistochemistry-Paraffin
Optimal dilutions of this antibody should be experimentally determined.
Western Blot
Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Immunogen affinity purified
Formulation
PBS
Preservative
0.05% Sodium Azide
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C in the dark.
Background: PEG3
Alternate Names
DKFZp781A095, KIAA0287PW1, paternally expressed 3, paternally expressed gene 3, Zinc finger and SCAN domain-containing protein 24, ZNF904, ZSCAN24Kruppel-type zinc finger protein
Gene Symbol
PEG3
Additional PEG3 Products
Product Documents for PEG3 Antibody (OTI1E10) [FITC]
Product Specific Notices for PEG3 Antibody (OTI1E10) [FITC]
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...